QBRI-HSCI Symposium


Monday, January 10, 2022, 8:00am to 12:00pm


Virtual, via Zoom - register to receive the link via email

Register by clicking here.



Please join us for a symposium on type 1 diabetes presented by the Harvard Stem Cell Institute (HSCI) and Qatar Biomedical Research Institute (QBRI), focused on the latest advances in beta cell differentiation, cell replacement therapy, and autoimmune protection.

8:00-8:15 | WELCOME 
Larry Stanton, with remarks by Doug Melton and Omar El-Agnaf 

Evolving role for beta cell replacement in Type I diabetes 
Jim Markmann, MD, PhD
Claude E. Welch Professor of Surgery, Massachusetts General Hospital 

Navigating beta cell differentiation via genome-wide loss-of-function screening
Adrian Veres, PhD | HSCI Trainee
Postdoctoral Research Fellow, Harvard University 

Towards a robust manufacturing process for autologous iPSC-based therapies.
Ruud Hulspas, PhD
Director Process Development, Dana-Farber Cancer Institute 

9:55-10:20 | BREAK 

Genome-wide in vivo CRISPR screen in the study of pancreatic beta cell protection against autoimmune destruction in T1D
Peng Yi, PhD
Assistant Investigator and Co-Director, Genome Editing Core, Joslin Diabetes Center 

Immune Barriers to Beta Cell Replacement
Jason Gaglia, MD, MMSc
Director of Hood Center for the Prevention of Childhood Diabetes, Joslin Diabetes Center 

11:40-11:50 | WRAP UP + THANK YOU
Larry Stanton


qbri-hsci_symposium_program.pdf97 KB